Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases

RECOMMENDED

Genitourinary Cancer

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

Lancet Oncol.

Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Karyakin O, Kimura G, Matsubara N, Nahas WC, Nolè F, Rosenbaum E, Heidenreich A, Kakehi Y, Zhang A, Krissel H, Teufel M, Shen J, Wagner V, Higano C

Genitourinary CancerRadio-Oncology

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

BMC Cancer.

Heidenreich A, Gillessen S, Heinrich D, Keizman D, O'Sullivan JM, Carles J, Wirth M, Miller K, Reeves J, Seger M, Nilsson S, Saad F

doi: 10.1186/s12885-018-5203-y.

Genitourinary Cancer

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer

Eur J Nucl Med Mol Imaging.

Du Y, Carrio I, De Vincentis G, Fanti S, Ilhan H, Mommsen C, Nitzsche E, Sundram F, Vogel W, Oyen W, Lewington V

doi: 10.1007/s00259-017-3756-7.

Genitourinary Cancer

Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial

Eur J Cancer.

Parker C, Zhan L, Cislo P, Reuning-Scherer J, Vogelzang NJ, Nilsson S, Sartor O, O'Sullivan JM, Coleman RE

doi: 10.1016/j.ejca.2016.10.020.

Genitourinary CancerRadio-Oncology

Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group

Eur Urol Oncol.

O'Sullivan JM, Carles J, Cathomas R, Gomez-Iturriaga A, Heinrich D, Kramer G, Ost P, van Oort I, Tombal B

doi: 10.1016/j.euo.2019.02.007.

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer

Clin Genitourin Cancer.

Heinrich D, Bektic J, Bergman AM, Caffo O, Cathomas R, Chi KN, Daugaard G, Keizman D, Kindblom J, Kramer G, Olmos D, Omlin A, Sridhar SS, Tucci M, van Oort I, Nilsson S

doi: 10.1016/j.clgc.2017.08.020.

Genitourinary Cancer

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial

Lancet Oncol.

Saad F, Carles J, Gillessen S, Heidenreich A, Heinrich D, Gratt J, Lévy J, Miller K, Nilsson S, Petrenciuc O, Tucci M, Wirth M, Federhofer J, O'Sullivan JM; Radium-223 International Early Access Program Investigators

doi: 10.1016/

Genitourinary Cancer

Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer

Eur J Cancer.

van der Doelen MJ, Isaacsson Velho P, Slootbeek PHJ, Pamidimarri Naga S, Bormann M, van Helvert S, Kroeze LI, van Oort IM, Gerritsen WR, Antonarakis ES, Mehra N

doi: 10.1016/j.ejca.2020.05.001.

SPECIAL REPORT

Genitourinary Cancer

Related content

Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program

Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer

Effect of radium-223 dichloride (Ra-223) on hospitalisation: An analysis from the phase 3 randomised Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial

Radium-223 Within the Evolving Treatment Options for Metastatic Castration-resistant Prostate Cancer: Recommendations from a European Expert Working Group

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer

Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial

Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer

Traitement ciblé par le radium-223, émetteur de particules alpha, dans le cancer de la prostate avec métastases osseuses